Table 2.

Overall summary of AE

Characteristic	Capmatinib capsule								Capmatinib tablet		All n = 44 n (%)
	100 mg q.d. n = 3 n (%)	200 mg q.d. n = 4 n (%)	400 mg q.d. n = 3 n (%)	500 mg q.d. n = 4 n (%)	600 mg q.d. n = 4 n (%)	800 mg q.d. n = 4 n (%)	400 mg b.i.d. n = 4 n (%)	600 mg b.i.d. n = 3 n (%)	200 mg b.i.d. n = 3 n (%)	400 mg b.i.d. n = 12 n (%)
All deathsa	0	0	0	1 (25.0)	0	0	0	0	0	0	1 (2.3)
On‐treatment deathsb	0	0	0	0	0	0	0	0	0	0	0
Total number of patients experiencing ≥1 AE	3 (100)	3 (75.0)	2 (66.7)	4 (100)	4 (100)	4 (100)	4 (100)	3 (100)	3 (100)	12 (100)	42 (95.5)
Suspected to be drug‐related	2 (66.7)	2 (50.0)	2 (66.7)	3 (75.0)	4 (100)	3 (75.0)	4 (100)	2 (66.7)	3 (100)	12 (100)	37 (84.1)
SAE	0	1 (25.0)	0	1 (25.0)	1 (25.0)	1 (25.0)	1 (25.0)	0	1 (33.3)	1 (8.3)	7 (15.9)
Suspected to be drug‐related	0	0	0	0	1 (25.0)	0	0	0	1 (33.3)	0	2 (4.5)
AE leading to discontinuation	0	0	0	0	0	1 (25.0)	0	1 (33.3)	1 (33.3)	1 (8.3)	4 (9.1)
AE requiring dose interruption and/or reduction	2 (66.7)	2 (50.0)	1 (33.3)	3 (75.0)	4 (100)	2 (50.0)	2 (50.0)	2 (66.7)	0	8 (66.7)	26 (59.1)
Suspected to be drug‐related	1 (33.3)	0	1 (33.3)	2 (50.0)	3 (75.0)	1 (25.0)	1 (25.0)	1 (33.3)	0	7 (58.3)	17 (38.6)

^aAll deaths including those that occurred more than 28 days after discontinuation of study treatment are counted.

^bOn‐treatment deaths occurring up to 28 d after discontinuation of study treatment are counted.

AE, adverse event; SAE, serious adverse event.